Want to see EDSA full AI Analyst Report?
Top Page
Edesa Biotech
(NASDAQ:EDSA)
Select Model
Select Model
Rating:53Neutral
Price Target:
$5.00
▼(-4.76% Downside)
Action:Reiterated
Date:07/30/26
Edesa Biotech's overall score of 53 is primarily pressured by its pre-revenue status, persistent operating cash burn, and weak valuation metrics typical of clinical-stage biotechnology firms. The stock's technical posture also remains subdued, trading below key short-term moving averages. However, these risks are significantly offset by a pristine zero-debt balance sheet and highly encouraging corporate developments. Recent positive clinical data, robust insider confidence demonstrated by a $3.5 million PIPE financing, and strong cash conservation measures align leadership with shareholder interests and provide crucial fundamental support.
Positive Factors
Strong balance sheet (no debt)
A near-zero debt position and roughly $12.4M of equity materially reduce solvency and refinancing risk for a clinical-stage biotech. This provides durable financial flexibility to fund R&D and absorb trial timing variability, lengthening runway versus leveraged peers.
Negative Factors
Sustained cash burn
Consistent negative operating cash flow near $7.6M TTM means the company must repeatedly access external capital to fund development. Over months, this creates structural dilution risk and forces prioritization of programs if additional financing is delayed or less favorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet (no debt)
A near-zero debt position and roughly $12.4M of equity materially reduce solvency and refinancing risk for a clinical-stage biotech. This provides durable financial flexibility to fund R&D and absorb trial timing variability, lengthening runway versus leveraged peers.
Read all positive factors
Edesa Biotech (EDSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.77M
Dividend YieldN/A
Average Volume (3M)95.23K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue GrowthN/A
EPS Growth16.07%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume58,770
30 Day Avg. Volume95,231
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside300.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Edesa Biotech Business Overview & Revenue Model
Company Description
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline...
How the Company Makes Money
Edesa Biotech primarily generates cash from financing activities rather than from recurring product revenue. As a clinical-stage company without established commercialized products, its operations are generally funded through (1) proceeds from the...
Edesa Biotech Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -102.99K | -119.27K | -186.05K | -183.47K | -118.19K | -118.79K |
| EBITDA | -10.48M | -7.07M | -5.98M | -8.19M | -17.43M | -13.22M |
| Net Income | -10.44M | -7.19M | -6.17M | -8.37M | -17.55M | -13.34M |
Balance Sheet | ||||||
| Total Assets | 12.38M | 13.53M | 3.81M | 8.89M | 11.58M | 14.58M |
| Cash, Cash Equivalents and Short-Term Investments | 10.00M | 10.79M | 1.04M | 5.36M | 7.09M | 7.84M |
| Total Debt | 0.00 | 0.00 | 19.87K | 94.49K | 18.98K | 99.32K |
| Total Liabilities | 2.19M | 1.08M | 1.83M | 1.84M | 2.18M | 1.53M |
| Stockholders Equity | 10.20M | 12.45M | 1.98M | 7.05M | 9.39M | 13.06M |
Cash Flow | ||||||
| Free Cash Flow | -7.65M | -7.32M | -4.89M | -6.64M | -12.28M | -13.67M |
| Operating Cash Flow | -7.65M | -7.32M | -4.89M | -6.64M | -12.28M | -13.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -5.66K | -6.15K |
| Financing Cash Flow | 3.84M | 17.03M | 592.03K | 4.83M | 11.63M | 14.17M |
Edesa Biotech Technical Analysis
Neutral
5.25
Price Trends
6.41
Negative
7.97
Negative
4.98
Positive
Market Momentum
-0.54
Negative
39.65
Neutral
49.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDSA, the sentiment is Neutral. The current price of 5.25 is below the 20-day moving average (MA) of 5.72, below the 50-day MA of 6.41, and above the 200-day MA of 4.98, indicating a neutral trend. The MACD of -0.54 indicates Negative momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 49.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EDSA.
Edesa Biotech Risk Analysis
Edesa Biotech disclosed 55 risk factors in its most recent earnings report. Edesa Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Edesa Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $54.55M | -3.87 | 76.02% | ― | ― | -13.32% | |
53 Neutral | $50.77M | -3.93 | -82.34% | ― | ― | 16.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $52.03M | -0.83 | -91.94% | ― | 106.65% | 12.20% | |
42 Neutral | $60.29M | -1.67 | -117.24% | ― | 476.71% | 70.23% | |
41 Neutral | $50.25M | -1.05 | -39.76% | ― | ― | 40.85% | |
41 Neutral | $41.52M | -1.11 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
EDSA
Edesa Biotech
5.24
3.13
148.34%
TIL
Instil Bio
7.41
-20.94
-73.86%
TCRX
TScan Therapeutics
0.77
-0.84
-52.36%
INKT
MiNK Therapeutics
10.95
-1.27
-10.39%
XLO
Xilio Therapeutics
9.20
-0.32
-3.38%
TVGN
Tevogen Bio Holdings
6.39
-42.61
-86.96%
Edesa Biotech Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Edesa Biotech Announces Insider-Led PIPE Financing Agreement
Positive
Jun 11, 2026
On June 10, 2026, Edesa Biotech, Inc. entered into a securities purchase agreement for a private placement of 729,241 common shares expected to raise approximately $3.5 million in gross proceeds. The financing, structured as a PIPE and led by the ...
Business Operations and StrategyProduct-Related Announcements
Edesa Biotech Reports Exploratory Kidney Outcomes Data in ARDS
Positive
Jun 5, 2026
On June 5, 2026, Edesa Biotech reported new exploratory data showing that its anti-TLR4 monoclonal antibody paridiprubart, combined with standard of care, reduced mortality and improved kidney-specific outcomes in hospitalized patients with acute ...
Executive/Board ChangesShareholder Meetings
Edesa Biotech Shareholders Approve Directors and Compensation Plans
Positive
May 29, 2026
On May 27, 2026, Edesa Biotech shareholders held their 2026 Annual General and Special Meeting, with approximately 55% of outstanding common shares represented, and elected seven directors to serve until the 2027 annual meeting or until successors...
Business Operations and StrategyExecutive/Board Changes
Edesa Biotech Boosts CEO Equity-Based Compensation Structure
Positive
May 15, 2026
On May 13, 2026, Edesa Biotech’s board approved a change to Chief Executive Officer Pardeep Nijhawan’s compensation structure, allowing 90% of his monthly base salary to be paid in fully vested restricted share units under the company&...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.